Large Benefit From Ovarian Function Suppression in Breast Cancer ...Middle East

Medscape - News
Eight-year follow-up of the ASTRRA trial confirms and extends support for adding 2 years of ovarian function suppression with goserelin to tamoxifen, compared with tamoxifen alone. Medscape Medical News

Hence then, the article about large benefit from ovarian function suppression in breast cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Large Benefit From Ovarian Function Suppression in Breast Cancer )

Apple Storegoogle play

Last updated :

Also on site :